Obstructive sleep apnoea with obesity — evidence across compounds
Every compound the Institute assesses in obstructive sleep apnoea with obesity, with its certainty rating.
§2Evidence across compounds
Every compound the Institute assesses in this indication, with the effect as recorded, the certainty rating and the contributing trials. Effects are reported on the anchor outcome where the contributing trials measured it and on the outcome the trial actually reported where they did not.
Table 1. Compounds assessed in obstructive sleep apnoea with obesity, ordered by certainty.
| Compound | Effect as recorded | Interval as reported | Certainty | Trials |
|---|---|---|---|---|
| TirzepatideDual GIP and GLP-1 receptor agonist (acylated) | Apnoea–hypopnoea index reduced by 25.3 events/hour versus 5.3 with placebo in participants not using positive airway pressure | estimated difference −20.0 events/hour (95 % CI −25.8 to −14.2) | High | 2 |
| LiraglutideGLP-1 receptor agonist (acylated, once-daily) | Apnoea–hypopnoea index reduced by 12.2 events/hour versus 6.1 with placebo at 32 weeks | estimated difference −6.1 events/hour (95 % CI −11.0 to −1.2) | Moderate | 1 |
| RetatrutideTriple GIP, GLP-1 and glucagon receptor agonist (acylated) | Not yet reported | — | Not rated | 1 |
| Estimates in this table are not on a common scale and must not be subtracted from one another. Where a comparison between two compounds has been made directly, it appears in a synthesis and not here. | ||||
§2.1Syntheses bearing on this indication
- Weight-reducing agents for obstructive sleep apnoea — Moderate
- Tirzepatide in obstructive sleep apnoea with obesity: effect on the anchor outcome — High
- Tirzepatide in obstructive sleep apnoea with obesity: tolerability and discontinuation — High
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine 2022;387(3):205–216. doi:10.1056/NEJMoa2206038 · PMID 35658024
- Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet 2023;402(10402):613–626. doi:10.1016/S0140-6736(23)01200-X · PMID 37385275
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.